Patient- and facility-level factors associated with diffusion of a new antipsychotic in the VA health system

Psychiatric Services

Volumn 57, Issue 1, 2006, Pages 70-76

  Valenstein, Marcia ^a,b,e   McCarthy, John F ^a,b   Ignacio, Rosalinda V ^c   Dalack, Gregory W ^a,b   Stavenger, Thomas ^d   Blow, Frederic C ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c SMITREC   (United States)

^d VA VISN 11 Headquarters   (United States)

^e Ann Arbor Center for Excellence   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; NEW DRUG; ZIPRASIDONE;

ADULT; AGE; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG USE; FEMALE; HEALTH CARE FACILITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; RACE DIFFERENCE; REGISTER; SCHIZOPHRENIA; SEX DIFFERENCE; UNITED STATES; VETERAN;

AGED; ALGORITHMS; ANTIPSYCHOTIC AGENTS; DRUG APPROVAL; DRUG THERAPY; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; PIPERAZINES; REGISTRIES; SCHIZOPHRENIA; THIAZOLES; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 30044452725     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.57.1.70     Document Type: Article

References (29)

1. Rogers EM: Diffusion of Innovations. New York, Free Press, 1995
2. McKinlay JB: From promising report to standard procedure: seven stages in the career of a medical innovation. Milbank Memorial Fund Quarterly 59:374-411, 1981
3. National Commission: The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC, US Government Printing Office, 1979
4. Garrison GD, Levin GM: Factors affecting prescribing of the newer antidepressants. Annals of Pharmacotherapy 34:10-14, 2000
5. Sclar DA, Robison LM, Skaer TL, et al: What factors influence the prescribing of antidepressant pharmacotherapy? An assessment of national office-based encounters. International Journal of Psychiatry in Medicine 28:407-419, 1998
6. Owen RR, Feng W, Thrush CR, et al: Variations in prescribing practices for novel antipsychotic medications among Veterans Affairs hospitals. Psychiatric Services 52: 1523-1525, 2001
7. Kuno E, Rothbard AB: Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. American Journal of Psychiatry 159:567-572, 2002
8. Mark TL, Dirani R, Slade E, et al: Access to new medications to treat schizophrenia. Journal of Behavioral Health Services and Research 29:15-29, 2002
9. Copeland LA, Zeber JE, Valenstein M, et al: Racial disparity in the use of atypical antipsychotic medications among veterans. American Journal of Psychiatry 160:1817-1822, 2003
10. Daumit GL, Crum RM, Guallar E, et al: Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Archives of General Psychiatry 60:121-128, 2003
11. Miller AL, Hall CS, Buchanan RW, et al: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. Journal of Clinical Psychiatry 65:500-508, 2004
12. VA Pharmacy Benefits Management Strategic Healthcare Group: Recommendations for Atypical Antipsychotic Use in Schizophrenia and Schizoaffective Disorders. Washington, DC, Department of Veterans Affairs, June 2002, last updated May 2004
13. Schooler NR: Maintaining symptom control: review of ziprasidone long-term efficacy data. Journal of Clinical Psychiatry 64(suppl 19):26-32, 2003
14. Kashner TM: Agreement between administrative files and written medical records: a case of the Department of Veterans Affairs. Medical Care 36:1324-1336, 1998
15. Szeto HC, Coleman RK, Gholami P, et al: Accuracy of computerized outpatient diagnoses in a Veterans Affairs general medicine clinic. American Journal of Managed Care 8:37-43, 2002
16. Valenstein M, Copeland LA, Blow FC, et al: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 40: 630-639, 2002
17. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. Journal of Chronic Disease 40:373-383, 1987
18. Miller AL: TIMA Procedural Manual: Schizophrenia Module, 2003
19. United States, by Region: Eastern, Central, Southern, Western. Washington, DC, Veterans Health Services and Research Administration, 1991
20. Zeger SL, Liang KY: Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121-130, 1986
21. Bobes J, Rejas J, Garcia-Garcia M, et al: Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: results of the EIRE study. Schizophrenia Research 62:77-88, 200.3
22. Homel P, Casey D, Allison DB: Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophrenia Research 55:277-284, 2002
23. Cooper LA, Gonzales JJ, Gallo JJ, et al: The acceptability of treatment for depression among African-American, Hispanic, and white primary care patients. Medical Care 41:479-489, 2003
24. Valenstein M, Blow FC, Copeland L, et al: Poor adherence with antipsychotic medication among patients with schizophrenia: patient and medication factors. Schizophrenia Bulletin 30:25,5-264, 2004
25. Ashton CM, Haidet P, Paterniti DA, et al: Racial and ethnic disparities in the use of health services: bias, preferences, or poor communication? Journal of General Internal Medicine 18:146-152, 2003
26. Balsa AI, Seiler N, McGuire TG, et al: Clinical uncertainty and healthcare disparities. American Journal of Law and Medicine 29:203-219, 2003
27. Lasser KE, Allen PD, Woolhandler SJ, et al: Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:221,5-2220, 2002
28. MedWatch: The FDA Safety Information and Adverse Event Reporting Program, 2004. Washington, DC, US Food and Drug Administration, 2004
29. Rosenheck R, Fontana A: Utilization of mental health sendees by minority veterans of the Vietnam era. Journal of Nervous and Mental Disease 182:685-691, 1994